2025 年 7 月 28 日，启迪药业集团股份公司（以下简称"公司"） 收到公司 控股股东启迪科技服务有限公司（以下简称"启迪科服"）之一致行动人北京华 清投资有限公司（以下简称"华清投资"）股权解除质押的通知。 根据中国证券登记结算有限责任公司深圳分公司于 2025 年 7 月 28 日出具 的《投资者证券冻结信息》，华清投资已将质押给华龙证券股份有限公司的 2,270,000 股于 2025 年 7 月 25 日解除质押。（前次质押情况详见 2024 年 7 月 27 日刊登于《中国证券报》《证券时报》《上海证券报》和巨潮资讯网上的《关于控 股股东之一致行动人部分股权被质押的公告》，公告编号 2024-033） 证券代码：000590 证券简称：启迪药业 公告编号：2025-025 启迪药业集团股份公司 关于启迪科服之一致行动人部分股权解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 截至本公告日，华清投资持有公司 4,544,451 股，占公司总股本的 1.90%。本次解除质押股份 2,270,000 股后，华清投资持有的公司股份处于无质 ...

Core Viewpoint - A dramatic competition is unfolding in the capital market as Hunan Sailoxian Management Consulting Partnership successfully acquired a 24.47% stake in Qidi Pharmaceutical for 1.007 billion yuan, positioning itself as a potential new controlling shareholder [1][4][15] Group 1: Auction Details - The auction attracted eight bidders and garnered over 410,000 online viewers, with the bidding process extending to 138 rounds and 107 delays [5][6] - The starting price for the shares was approximately 450 million yuan, and the final bid represented a 124% premium over the starting price [7] - The auction price per share was about 17.19 yuan, while the closing price on the day of the auction was 13.86 yuan, indicating a significant price discrepancy [7] Group 2: Market Reactions - Following the auction, Qidi Pharmaceutical's stock experienced volatility, with a cumulative increase of 24.86% from July 9 to July 14, but a drop of 1.88% on July 15 [7][8] - The stock was listed on the Shenzhen Stock Exchange's "Dragon and Tiger List" due to its significant price fluctuations, with a notable sell-off from a specific brokerage [8][9] Group 3: Legal Context - The acquisition is set against a backdrop of a trademark infringement lawsuit initiated by Qidi Pharmaceutical against Hunan Hengchang Pharmaceutical, which is also linked to Hunan Sailoxian [10][11] - The lawsuit stems from allegations that Hengchang Pharmaceutical used Qidi's registered trademarks at a trade fair, leading to significant reputational damage for Qidi [10][11] Group 4: Financial Performance - Qidi Pharmaceutical has faced financial challenges, reporting a net loss of 125 million yuan in 2024 and an expected loss of 15 to 19 million yuan for the first half of the year [12] - The company's revenue has declined due to market conditions and rising material costs, impacting its overall profitability [12] Group 5: Future Implications - The potential acquisition raises questions about future asset injections and the strategic direction of Qidi Pharmaceutical under Hunan Sailoxian's control [16] - The relationship between Hunan Sailoxian and Hengchang Pharmaceutical may influence the resolution of ongoing legal disputes and the future operational strategy of Qidi Pharmaceutical [11][16]

Market Performance - As of July 21, the Shanghai Composite Index rose by 0.72%, closing at 3559.7912 points [1] - The Shenzhen Component Index increased by 0.86%, closing at 11007.487 points [1] Top Gainers in Hunan Stocks - Boyun New Materials opened at 7.910 and closed at 8.700, with a daily increase of 9.99% and a trading volume of 913,006 shares [2] - Yipuli opened at 14.100 and closed at 14.100, with a daily increase of 9.98% and a trading volume of 73,411 shares [2] - Shanhe Intelligent opened at 8.310 and closed at 8.820, with a daily increase of 9.98% and a trading volume of 967,465 shares [2] - Zhejiang Construction Investment opened at 9.210 and closed at 9.620, with a daily increase of 6.65% and a trading volume of 798,714 shares [2] - Changgao Electric New opened at 7.450 and closed at 7.680, with a daily increase of 6.37% and a trading volume of 779,409 shares [2] Top Losers in Hunan Stocks - Hengli Retreat opened at 0.160 and closed at 0.150, with a daily decrease of 11.76% and a trading volume of 611,606 shares [3] - Qidi Pharmaceutical opened at 12.430 and closed at 12.120, with a daily decrease of 2.96% and a trading volume of 173,563 shares [3] - Yueyang Xingchang opened at 18.080 and closed at 17.610, with a daily decrease of 2.87% and a trading volume of 122,456 shares [3] - ST Jiajia opened at 6.180 and closed at 6.060, with a daily decrease of 1.78% and a trading volume of 73,498 shares [3] - ST Jingfeng opened at 5.830 and closed at 5.760, with a daily decrease of 1.37% and a trading volume of 119,258 shares [3]

Core Viewpoint - The judicial auction of 58.607 million shares of Tsinghua Unigroup (启迪药业) has resulted in a significant change in the company's control, with Hunan Sailoxian Management Consulting Partnership winning the bid at 1.007 billion yuan, potentially altering the ownership structure of the company [2][3][4]. Group 1: Auction Details - The auction attracted over 400,000 online viewers and involved eight competitive buyers, culminating in 138 rounds of bidding and 107 extensions [2][3]. - Hunan Sailoxian, established on June 19, 2025, with a registered capital of 400 million yuan, won the auction, with its major shareholder being Jiang Xin, who also leads Hunan Hengchang Pharmaceutical [3]. Group 2: Ownership Changes - If the auction is finalized, Tsinghua Unigroup will completely exit its shareholder position, reducing its voting rights from 26.37% to 1.90%, while Hunan Sailoxian will become the largest shareholder with a 24.47% stake [3][4]. - The second-largest shareholder, Hengyang Hongxiang State Investment Group, holds 19.11% of the shares, indicating a close competition between state-owned and private entities [4]. Group 3: Legal Context - The auction stems from a financial dispute between Tsinghua Unigroup and the Agricultural Bank of China, leading to the shares being put up as collateral [2][3]. - Tsinghua Unigroup has previously engaged in legal action against Hengchang Pharmaceutical for trademark infringement, raising questions about future legal strategies post-control change [5].

Policy Developments - Shanghai is advancing the standardization research of medical accompaniment services, with a project led by East China Hospital identified as a key research topic for 2024, focusing on service institutions, personnel requirements, service processes, and quality evaluation [2] Drug and Device Approvals - Maike Bio has received a medical device registration certificate for its coagulation factor activity measurement kits, valid from July 8, 2025, to July 7, 2030, aimed at monitoring treatments for coagulation factor deficiencies [3] - Kewang Pharmaceutical's vitamin K1 drops have received a registration acceptance notice from the National Medical Products Administration, intended to prevent vitamin K deficiency bleeding in infants [4] - CanSino has been approved for clinical trials of its trivalent poliovirus vaccine, which is being developed using protein structure design and VLP assembly technology, currently undergoing I/II phase trials in Indonesia [5] Financial Reports - Johnson & Johnson reported Q2 revenue of $23.74 billion, a 5.8% increase year-over-year, exceeding market expectations, with projected annual sales between $93.2 billion and $93.6 billion [6] Capital Markets - Tuoxin Pharmaceutical plans to invest 10 million yuan in Jiangsu Jinsan Biotechnology Co., acquiring a 1.75% stake, with Jinsan successfully producing high-purity ergothioneine for various products [7] - Tsinghua Unigroup's stock auction resulted in the sale of 58.607 million shares, potentially leading to a change in control of the company, with the shares sold at an average price significantly above the latest closing price [8] Industry Events - China National Pharmaceutical Group responded to rumors regarding the "return" of a licensing agreement with Merck for a PD-1/VEGF bispecific antibody, stating that the collaboration is progressing normally and a milestone payment of $300 million is expected upon completion of technology transfer by 2025 [9] Public Sentiment Alerts - A senior executive of Astellas Pharma in China was sentenced to three and a half years in prison for espionage, highlighting potential risks in the pharmaceutical industry [10] Stock Market Alerts - ST Weiming's stock has been placed under risk warning due to a significant price drop and expected losses of 55 million to 85 million yuan for the first half of 2025, leading to a change in its trading name and restrictions on price fluctuations [11]

Market Overview - On July 16, the Shanghai Composite Index fell by 0.03%, with institutional investors appearing on the trading lists of 25 stocks, net buying 11 and net selling 14 [1][2] - The total net selling amount by institutional investors reached 1.015 billion yuan [1] Institutional Trading Activity - The stock with the highest net buying by institutional investors was Huahong Technology, which closed at the daily limit with a trading volume of 1.919 billion yuan and a turnover rate of 27.83%. The net buying amount was 112.81 million yuan [2][5] - Other notable stocks included Beifang Changlong, which rose by 6.59% with a turnover rate of 42.00% and a net buying amount of 70.49 million yuan [2][5] Performance of Net Bought Stocks - Stocks that were net bought by institutions saw an average increase of 5.35%, outperforming the Shanghai Composite Index. Stocks like Jujie Microfiber and Degute achieved daily limit increases [3] - Historical data indicates that stocks net bought by institutions have a 50.17% probability of rising the next day, with a 37.46% probability of increasing over the next three days [3] Earnings Forecasts - Among the stocks net bought by institutions, four have released half-year earnings forecasts, with Huahong Technology expected to see a net profit increase of 3384.71% [3] Net Sold Stocks - The stock with the highest net selling was C Huaxin, with a net selling amount of 999.70 million yuan. This stock had a significant net inflow of 3.172 billion yuan [3][6] - Annie Shares also saw substantial net selling, amounting to 247.11 million yuan, with a net outflow of 117 million yuan [3][6] Deep and Hong Kong Stock Connect Activity - On July 16, 12 stocks on the trading list had participation from the Shenzhen and Shanghai Stock Connect, with net buying in stocks like Hengbao Co. and Dawi Technology [7][8] - Hengbao Co. had a net buying amount of 160.75 million yuan, while stocks like Zhongdian Port and Qianhong Pharmaceutical experienced net selling [7][9]

Core Viewpoint - The recent judicial auction of 24.47% equity in Qidi Pharmaceutical by Hunan Sailuxian marks a significant shift in control, with potential implications for the company's future operations and market position [2][11]. Group 1: Auction Details - Hunan Sailuxian successfully acquired 24.47% of Qidi Pharmaceutical's shares for 1.007 billion yuan after 138 rounds of bidding, indicating strong market interest [2][5]. - The average price per share in this transaction was approximately 17.19 yuan, representing a 24% premium over the closing price on the auction day [5][11]. - The auction was prompted by a financial dispute between Qidi Pharmaceutical's controlling shareholder and a bank, leading to the judicial sale of pledged shares [4][12]. Group 2: Company Background and Implications - Qidi Pharmaceutical has been facing financial difficulties, with a reported revenue decline of 15.18% year-on-year and a net loss of 1.25 billion yuan in the previous year [11][12]. - The new major shareholder, Hunan Sailuxian, is linked to Jiang Lin, the founder of Hunan Hengchang Pharmaceutical, which has a complementary distribution network that could enhance Qidi Pharmaceutical's market reach [10][11]. - If the share transfer is completed, Qidi Pharmaceutical's current controlling shareholder will lose its majority stake, potentially altering the company's governance and strategic direction [11][12].

Core Viewpoint - The article discusses the significant change in control of Qidi Pharmaceutical due to a judicial auction, where Hunan Sailuxian successfully acquired a 24.47% stake in the company for 1.007 billion yuan, potentially leading to a change in the company's controlling shareholder [2][9][18]. Summary by Sections Auction Details - The auction for Qidi Pharmaceutical's shares took place from July 14 to July 15, 2025, after a delay due to objections from interested parties [7]. - Hunan Sailuxian won the auction with a bid of 1.007 billion yuan, translating to an average price of 17.19 yuan per share, which is approximately 24% higher than the closing price on the auction day [9][18]. Company Background - Qidi Pharmaceutical, listed under the stock code 000590, has been facing financial difficulties, with a reported revenue of 343 million yuan in 2024, down 15.18% year-on-year, and a net loss of 125 million yuan, a staggering decline of 596.98% [18]. - Hunan Sailuxian was established on June 19, 2025, with a registered capital of 400 million yuan, primarily controlled by Jiang Xin, who is also the founder and chairman of Hunan Hengchang Pharmaceutical Group [12][15]. Strategic Implications - The acquisition is seen as a strategic move to enhance the supply chain and profitability, as Hunan Hengchang's distribution network complements Qidi Pharmaceutical's product offerings [16]. - If the share transfer is completed, Qidi Pharmaceutical's current controlling shareholder, Qidi Technology Service Co., will lose its controlling status, reducing its voting rights from 26.37% to 1.90% [18]. Market Reaction - Following the auction news, Qidi Pharmaceutical's stock experienced significant volatility, with a nearly 50% increase in price over the month leading up to the auction [19].

Core Viewpoint - The controlling shareholder of Qidi Pharmaceutical, Qidi Technology Service Co., Ltd., has successfully auctioned 58.607 million shares, which may lead to a change in the company's control [1] Group 1: Share Auction Details - Qidi Pharmaceutical announced that 58.607 million shares held by its controlling shareholder were auctioned on JD.com’s judicial auction platform [1] - The successful bidder, Hunan Sailoxian Management Consulting Partnership, acquired the shares for a total price of 1.007 billion yuan, averaging 17.19 yuan per share [1] - This auction price is significantly higher than the company's latest closing price of 13.86 yuan per share [1] Group 2: Potential Control Change - If the judicial auction is completed and the share transfer is executed, Hunan Sailoxian will hold 58.607 million shares, representing 24.47% of the company's total share capital [1] - This acquisition may result in Hunan Sailoxian obtaining control over Qidi Pharmaceutical [1]

Group 1 - The core point of the news is that the controlling shareholder of Qidi Pharmaceutical, Qidi Technology Service Co., Ltd., has auctioned off 58,606,962 shares, which represents 24.47% of the company's total share capital, potentially leading to a change in control of the company [1][5]. - The auction of the shares was initially scheduled for November 28, 2024, but was postponed due to objections from interested parties [3]. - The shares were successfully auctioned, but the final transfer of ownership is pending confirmation from the Beijing Financial Court [1][3]. Group 2 - Prior announcements regarding the potential judicial auction of the controlling shareholder's shares were made on October 30, 2024, and further updates were provided on June 17, 2025 [2][3]. - If the auctioned shares are fully transferred, Qidi Technology Service will no longer hold any shares in the company, and its voting rights will decrease significantly to 1.90% of the total share capital [5]. - The company emphasizes that the auction will not have a significant impact on its operations or governance, as it remains independent from the controlling shareholder [5].